WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 1, 2019--
Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company
focused on developing and commercializing novel tetracyclines to treat
serious and life-threatening conditions, today announced that senior
management will present a corporate overview at the H. C. Wainwright and
Company Global Life Sciences Conference on Monday, April 8, 2019 at 9:10
a.m. GMT at the Grosvenor House JW Marriott Hotel in London, UK and at
the 18th Annual Needham Healthcare Conference on Wednesday,
April 10, 2019 at 2:50 p.m. ET at the Westin Grand Central Hotel in New
Live audio webcasts of both presentations will be available on the
Company’s website at https://tphase.gcs-web.com/events-presentations.
The archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using
its proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including bacterial infections
caused by many of the multidrug-resistant bacteria highlighted as urgent
public health threats by the World Health Organization and the Centers
for Disease Control and Prevention. The Company has created more than
3,000 novel tetracycline compounds using its proprietary technology
platform. Tetraphase's lead product XERAVATM is approved for
the treatment of complicated intra-abdominal infections by the U.S. Food
and Drug Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical
trials and TP-2846 which is in preclinical testing for acute myeloid
leukemia. Please visit www.tphase.com
for more company information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005629/en/
Source: Tetraphase Pharmaceuticals, Inc.